Clinical Trials

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06697301 2026-05-08

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

740 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

135 enrolled

Melanoma

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

118 enrolled

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

230 enrolled

Lung Neoplasms

NCT06236438 2026-02-23

LIVIGNO-4

840 enrolled

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

420 enrolled

Uveal Melanoma, Melanoma

NCT04619797 2026-02-03

SKYSCRAPER-06

542 enrolled

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

450 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

720 enrolled

Squamous NSCLC

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Phase 2/3 Active not recruiting

52 enrolled

Advanced or Metastatic Solid Malignancies

NCT06082167 2025-08-17

STELLAR-305

600 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT06923475 2025-04-11

NEODISCO

Phase 2/3 Not yet recruiting

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

700 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06907602 2025-04-02

ONTRESCC

120 enrolled

Esophageal Squamous Cell Carcinoma

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04322617 2024-06-04

ATHENA

1,200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

172 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/3 Terminated

1 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05429697 2022-09-27

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

128 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

15 enrolled

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT01905657 2021-10-06

MK-3475-010

1,034 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

700 enrolled